Latest filing published 03 Sept 2026 for Entrada Therapeutics, Inc., €54k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Filings by Dipal Doshi span 2 companies, the busiest being Entrada Therapeutics, Inc. and Azenta, Inc. Between 13 January 2022 and 2 September 2026, the trades on record add up to 41 filings.
On the market, this insider has only sold: 27 sales, €618k in total. Other entries cover 13 share grants and 1 option exercise.
The latest filing, published on 3 September 2026, reports a share grant of €54k in Entrada Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 41 declarations